Michiel S. van der Heijden
A5031163075- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Immune cells in cancer
- Cancer Research and Treatments
- Prostate Cancer Treatment and Research
- Signaling Pathways in Disease
- Ferroptosis and cancer prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Genital Health and Disease
- Chromatin Remodeling and Cancer
- S100 Proteins and Annexins
- Neuroendocrine Tumor Research Advances
- DNA Repair Mechanisms
- Fibroblast Growth Factor Research
- Prostate Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Nanoplatforms for cancer theranostics
- Urologic and reproductive health conditions
The Netherlands Cancer Institute
2016-2025
Oncode Institute
2015-2024
Queen Mary University of London
2024
University of Sheffield
2024
Barts Health NHS Trust
2024
Sheffield Teaching Hospitals NHS Foundation Trust
2024
Icahn School of Medicine at Mount Sinai
2016-2023
Dana-Farber Cancer Institute
2023
University Medical Center Utrecht
2023
Hubrecht Institute for Developmental Biology and Stem Cell Research
2023
Selective sequencing or in silico analysis for differences DNA fragment size can improve the detection of circulating tumor DNA.
Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the phosphatase gene superfamily human cancers identified 83 somatic mutations six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% colorectal a smaller fraction lung, breast, gastric cancers. Fifteen were nonsense, frameshift, or splice-site alterations predicted to result truncated proteins...
No treatment has surpassed platinum-based chemotherapy in improving overall survival patients with previously untreated locally advanced or metastatic urothelial carcinoma. Download a PDF of the Research Summary. We conducted phase 3, global, open-label, randomized trial to compare efficacy and safety enfortumab vedotin pembrolizumab Patients were randomly assigned 1:1 ratio receive 3-week cycles (at dose 1.25 mg per kilogram body weight intravenously on days 1 8) 200 day 1) (enfortumab...
Abstract The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment 171) ctDNA samples across 16 advanced-stage types from three phase I/II trials durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher variant allele frequencies (VAF) were associated poorer overall survival (OS) other known prognostic factors, but not objective response, suggesting role...
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.In this phase 3, multinational, open-label trial, we randomly assigned previously untreated either receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up six cycles, followed by 480 4 maximum 2 years, alone cycles. The primary outcomes were and progression-free...
Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. With the recent development of novel treatments, accurate stratification strategies are needed. Here we present whole-genome sequencing (WGS) analysis fresh-frozen metastatic biopsies from 197 mCRPC patients. Using unsupervised clustering based on features, define eight distinct clusters. We observe potentially clinically relevant genotypes, including microsatellite instability (MSI), homologous...
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes.
To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC).We analysed a multi-institutional cohort of 1082 treated upfront RC cT1-4aN0M0 BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect different VHs on DSS overall three stage-based analyses. The stages defined as 'organ-confined' (≤pT2N0), 'locally advanced' (pT3-4N0)...